What question did this study set out to answer?

This study aims to evaluate the pharmacodynamic effects, safety, and pharmacokinetics of orally administered kratom and its alkaloids.

March 18, 2026

A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom

Key Points

This study aims to evaluate the pharmacodynamic effects, safety, and pharmacokinetics of orally administered kratom and its alkaloids.
Conducted a pilot, double-blind, between-subjects study with 40 recreational polydrug users.
Monitored adverse events, vital signs, and conducted laboratory tests for safety assessments.
Administered varied doses of kratom (1, 3, 8, 10, and 12 g) following safety reviews.
Utilized pupillometry and subjective effect assessments to evaluate drug response.
No deaths or serious adverse events occurred during the study.
Common adverse effects included somnolence, vomiting, and nausea.
Kratom exhibited dose-related pharmacodynamic effects, especially at doses ≥3 g.
The highest dose (12 g) increased subjective measures such as drug liking and good effects.

Abstract

Background: Kratom ( Mitragyna speciosa ) is a plant indigenous to Southeast Asia. This pilot study evaluated the pharmacodynamic (PD) effects, safety, and pharmacokinetics (PK) of kratom and several of its alkaloids. Methods: Recreational polydrug users (8 participants/cohort; 6 active: 2 placebo, N=40) completed the study. Participants had experience with opioids but were otherwise healthy. This study utilized a double-blind, between-subjects design where participants randomly received a single dose of placebo or kratom. The kratom used in the study had alkaloid levels representative of botanical kratom products (i.e., leaf) previously characterized in the literature and contained trace levels of 7-hydroxymitragynine (7-OH). The starting dose was 1 g and doses of 3, 8, 10, and 12 g were administered after safety reviews after each dose. After dosing, pupillometry and assessments of subjective effects were performed, and blood samples were collected. Safety assessments included adverse events (AE) monitoring, laboratory tests, vital signs, ECG assessments, physical examination findings, and assessment of suicidality. Results: No deaths or serious adverse events (SAEs) occurred. Somnolence, vomiting, and nausea were the most common AEs reported. Kratom alkaloid concentrations showed generally orderly, dose-related effects. At doses ≥3 g, kratom produced pupillary constriction. Few dose-related effects were observed, although the 12 g dose of kratom produced increases on several subjective measures including ratings of “drug liking.” Conclusions: This study investigated the safety of single-sourced botanical kratom; the results may not be representative of other kratom-containing products. Kratom produced some opioid-like effects including pupillary constriction, and the 12 g dose produced effects commonly associated with drugs of abuse such as visual analog scale (VAS) ratings of drug liking, good effects, and high.

Bookmark

A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom

Key Points

Abstract

Cite This Study

Also Consider

Also Consider